查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1883720

肽類藥物市場：產業趨勢及全球預測（至2040年）－依給藥途徑、治療領域及地區劃分

Peptide Therapeutics Market: Industry Trends and Global Forecasts, Till 2040 - Distribution by Type of Peptide, Route of Administration, Key Therapeutic Area and Geographical Regions
出版日期: | 出版商: Roots Analysis | 英文 250 Pages | 商品交期: 最快1-2個工作天內

價格

勝肽類藥物市場：市場概覽

根據Roots Analysis預測，勝肽類藥物市場規模預計將從目前的842億美元增長至2035年的1624億美元，預測期內（至2035年）複合年增長率（CAGR）為6.8%。

勝肽類藥物市場

市場規模和機會分析基於以下參數進行區隔：

給藥途徑

  • 靜脈注射
  • 口服
  • 皮下注射
  • 局部用藥
  • 其他

主要治療領域

  • 代謝性疾病
  • 腫瘤
  • 內分泌疾病
  • 消化和胃腸道疾病
  • 其他

地理區域

  • 北美
  • 歐洲
  • 亞太地區
  • 世界其他地區

勝肽類藥物市場：成長與趨勢

勝肽類藥物是一類藥物。利用多肽開發的藥物可用於治療多種疾病。天然存在的勝肽通常發揮生長因子、荷爾蒙、神經傳導物質、抗感染劑和離子通道配體等功能。這些勝肽已被用於開發基於勝肽的療法，這些療法常用於治療代謝性疾病、癌症和荷爾蒙相關疾病。值得注意的是，已有超過100種基於勝肽的療法在多個國家獲得FDA批准。已核准的勝肽療法包括替澤帕肽（Mounjaro®）、镥-177標記的比匹博肽四西坦（Pluvicto®）和Lupkynis™。由於糖尿病、骨關節炎、肥胖症、自體免疫疾病、類風濕性關節炎和癌症等慢性疾病的盛行率不斷上升，近年來對生物製劑的需求日益增長。

生物製劑，如重組蛋白和勝肽，具有多項優勢，包括靶向特異性高、安全性好、毒性低以及脫靶效應風險低。尤其值得一提的是，許多製藥公司正致力於開發創新藥物偶聯物，包括勝肽類藥物和細胞穿透勝肽，以應對多種疾病。此外，該領域的最新進展已促成勝肽類藥物獲準並應用於臨床，用於治療第二型糖尿病、肥胖症和多種癌症等疾病。一般認為，該市場在不久的將來有望實現顯著成長。

勝肽類藥物市場：關鍵洞察

本報告深入分析了勝肽類藥物市場的現狀，並指出了該行業的潛在成長機會。主要發現包括：

  • 勝肽類藥物是當今成長最快的藥物類別之一，目前已有 25 種核准藥物和超過 280 種候選藥物正在研發中，能夠治療多種疾病。
勝肽類藥物市場-IMG1
  • 目前正在研發的勝肽類藥物種類繁多，涵蓋多種給藥途徑，主要用於治療代謝性疾病和腫瘤疾病。
  • 面對眾多極具潛力的候選藥物帶來的日益激烈的競爭，創新者們正致力於在臨床和商業層面實現產品差異化。
  • 全球已註冊超過1200項以勝肽類藥物為重點的臨床試驗，其中大多數研究目前正在評估旨在治療代謝性疾病的候選產品。
  • 人們對該領域日益增長的興趣也體現在近期合作活動的增加上，其中大部分合作集中在技術和/或產品授權方面。
勝肽類藥物市場-IMG2
  • 眾多公私部門投資者預期該領域將獲得豐厚回報，已透過200多項交易投資超過70億美元。
勝肽類藥物市場-IMG3
  • 為了把握這個快速成長市場的豐厚機遇，多家大型製藥公司正在採取各種舉措，從自主研發產品到策略性投資。
  • 憑藉著前景廣闊的研發管線和令人鼓舞的臨床結果，預計未來十年肽類藥物市場將以每年 6.8% 的速度成長。

勝肽類藥物市場：主要區隔市場

中等大小的勝肽佔勝肽類藥物產業最大的佔有率

今年，中等大小的勝肽佔了大部分市場佔有率（約 65%）。這可能是因為中等大小的勝肽（10-40個胺基酸）在大蛋白和小分子之間取得了有效的平衡。值得注意的是，由於小肽在標靶藥物生產中的應用日益廣泛，預計其在預測期內的複合年增長率將超過20%。

皮下給藥引領勝肽類藥物市場

整個市場分為靜脈注射、口服、皮下注射、局部用藥和其他給藥途徑。今年，皮下給藥途徑佔總市佔率的65%以上。皮下給藥繞過了胃腸道和肝臟（首過效應），從而提高了治療效果。由於對非侵入性或標靶給藥途徑的需求持續成長，預計局部用藥途徑在預測期內的複合年增長率將達到約30%。

代謝性疾病領域預計將佔勝肽類藥物市場最大的佔有率。

目前，代謝性疾病領域預計將佔整個市場的60%以上。這主要歸功於人們對基於勝肽的療法在改善糖尿病和肥胖等代謝性疾病方面的需求不斷增長。特別是，用於治療胃腸道疾病的勝肽類藥物市場預計在預測期內將以25%的複合年增長率高速成長。

未來幾年，北美將引領肽類藥物產業的發展。

本部分重點分析了北美、歐洲和亞太地區等各地區的市場分佈。根據預測，北美今年將佔大部分市場佔有率，而這一趨勢預計將持續下去。根據美國疾病管制與預防中心的報告，美國約有1.29億人患有至少一種慢性疾病，例如糖尿病、肥胖、心臟病或高血壓。這推動了該地區對肽類藥物的需求。值得注意的是，亞太市場在預測期內可望以相對較高的複合年增長率成長。

勝肽類藥物市場代表性公司

  • Apellis Pharmaceuticals
  • BioLineRx
  • Eli Lilly
  • FirstString Research
  • Novo Nordisk
  • Palatin Technologies
  • RegeneRx Biopharmaceuticals
  • Stealth BioTherapeutics
  • Takeda
  • Zealand Pharma

勝肽類藥物市場：研究範圍

  • 市場規模和機會分析：本報告對肽類藥物市場進行了詳細分析，重點關注以下關鍵市場區隔：[A] 肽類型，[B] 給藥途徑，[C] 主要治療領域，以及 [D] 地理區域。
  • 市場概況：基於相關參數（例如[A]研發階段、[B]勝肽類型、[C]給藥途徑、[D]主要治療領域、[E]成立年份、[F]公司規模和[G]總部所在地）對目前已獲批准或正在研發的300多種勝肽類療法進行詳細評估。
  • 公司簡介：詳細介紹活躍於該領域的主要公司，重點關注[A]成立年份、[B]總部所在地、[C]肽類詳情、[D]近期進展和[E]未來展望。
  • 領先的製藥計畫：基於多個參數（例如[A]胺基酸數量、[B]給藥途徑和[C]治療領域）對在治療性勝肽領域運作的主要生物製藥公司進行分析。
  • 合作夥伴關係與合作：基於[A]合作年份、[B]合作類型、[C]合作夥伴類型和[D]主要參與者等相關參數，對肽類藥物市場利益相關者之間的合作夥伴關係與合作進行深入分析。
  • 融資與投資分析：基於[A]融資年份、[B]投資金額、[C]融資類型、[D]區域分佈和[E]最活躍參與者等相關參數，對肽類藥物開發商籌集的各種資金和投資進行全面分析。
  • 臨床試驗分析：基於[A]試驗註冊年份、[B]研發階段、[C]當前試驗狀態和[D]入組患者群體等相關參數，對各種治療性勝肽的已完成、正在進行和計劃中的臨床試驗進行深入分析。
  • 案例研究1：本案例研究重點關注在勝肽類藥物市場中運作的服務提供者的角色。它涵蓋了積極參與該領域的各類合約研究組織 (CRO)、合約生產組織 (CMO) 和客製化勝肽類藥物生產商的資訊。
  • 案例研究 2：本案例研究介紹了新型勝肽類藥物的關鍵特徵，並提供了有關其應用領域、優勢以及研發過程中主要挑戰的資訊。

目錄

第一章：前言

第二章：摘要整理

第三章：導論

  • 章節概要
  • 勝肽的結構
  • 勝肽的分類
  • 勝肽的修飾
  • 勝肽療法的發展
  • 勝肽療法的設計與開發
  • 勝肽療法的優點與缺點
  • 勝肽療法的應用
  • 未來展望

第四章：市場概覽

  • 章節概要

第四章 2. 勝肽治療藥物：市場概覽

    • 依研發階段分析
    • 依肽類型分析
    • 依給藥途徑分析
    • 依研發階段及給藥途徑分析
    • 依治療領域分析
    • 依研發階段及治療領域分析
    • 依給藥途徑及治療領域分析
    • 依研發階段、給藥途徑及治療領域分析（網格視圖）

第五章 競爭格局

第六章 公司簡介

  • 章節概述
  • Apellis P製藥公司
  • BioLineRx
  • 禮來
  • FirstString Research
  • 諾和諾德
  • Palatin Technologies
  • RegeneRx Biopharmaceuticals
  • Stealth BioTherapeutics
  • 武田
  • Zealand Pharma

第七章：主要藥廠在勝肽類藥物領域的努力

  • 章節概述
  • 主要藥廠：在勝肽類藥物領域的努力
  • 關鍵參數基準分析
  • 主要藥廠基準分析

第八章：合作關係與合作

第九章 資金與投資分析

  • 章節概述
  • 資金類型
  • 勝肽類藥物：資金與投資分析

第十章：臨床試驗分析

  • 章節概述
  • 研究範圍與方法
  • 勝肽類藥物：臨床試驗分析

第十一章 臨床與商業吸引力分析

  • 章節概述
  • 研究方法
  • 相關見解
    • 臨床與商業吸引力分析：自體免疫疾病
    • 臨床和商業吸引力分析：中樞神經系統 (CNS) 疾病
    • 臨床與商業吸引力分析：內分泌疾病疾病
    • 臨床與商業吸引力分析：胃腸道疾病
    • 臨床與商業吸引力分析：遺傳性疾病
    • 臨床與商業吸引力分析：血液系統疾病
    • 臨床與商業吸引力分析：傳染病
    • 臨床與商業吸引力分析：發炎性疾病
    • 臨床與商業吸引力分析：代謝性疾病
    • 臨床與商業吸引力分析：腫瘤疾病
    • 臨床與商業吸引力分析：眼科疾病
    • 臨床與商業吸引力分析：其他疾病

第12章案例研究：合約服務的現況

  • 章節概述
  • 服務提供者的角色
  • 外包的優勢
  • 相關的風險與挑戰外包

第十三章：案例研究：新型勝肽療法

  • 章節概述
  • 新型勝肽療法概述
  • 新型勝肽療法的優點與應用
  • 新型勝肽療法面臨的主要挑戰

第十四章：市場預測與機會分析

  • 章節概述
  • 範圍和局限性
  • 關鍵假設與預測研究方法
  • 2030年全球勝肽療法市場展望
  • 自體免疫疾病
  • 心血管疾病
  • 中樞神經系統疾病
  • 皮膚病
  • 內分泌疾病
  • 胃腸道疾病
  • 遺傳性疾病疾病
  • 血液系統疾病
  • 傳染病
  • 發炎性疾病
  • 代謝性疾病
  • 腫瘤疾病
  • 眼科疾病
  • 其他

第15章：結論

  • 章節概述

第16章：附錄一：已核准的勝肽類藥物清單

第17章：附錄二：表格資料

第18章：附錄三：公司與組織清單

Product Code: RA100268

PEPTIDE THERAPEUTICS MARKET: OVERVIEW

As per Roots Analysis, the peptide therapeutics market is estimated to grow from USD 84.2 billion in the current year to USD 162.4 billion by 2035, at a CAGR of 6.8% during the forecast period, till 2035.

Peptide Therapeutics Market

The market sizing and opportunity analysis has been segmented across the following parameters:

Route of Administration

  • Intravenous
  • Oral
  • Subcutaneous
  • Topical
  • Other

Key Therapeutic Area

  • Metabolic Diseases
  • Oncological Diseases
  • Endocrine Diseases
  • Digestive and Gastrointestinal Diseases
  • Others

Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Peptide Therapeutics Market: Growth and Trends

Peptide therapeutics are a class of medications developed with polypeptides to cater to various illnesses. Generally, naturally occurring peptides can serve as growth factors, hormones, neurotransmitters, anti-infectives, and ligands for ion channels. Such peptides have been utilized in creating peptide-based therapies that are commonly employed in treating metabolic diseases, cancer, and hormone-related treatments. It is noteworthy that more than 100 peptide-based therapies have been authorized by the FDA in various nations. Examples of recognized peptide therapeutics include Tirzepatide (Mounjaro(R)), Lutetium Lu-177 vipivotide tetraxetan (Pluvicto(R)), and Lupkynis(TM). Driven by the rising prevalence of chronic conditions, such as diabetes, osteoarthritis, obesity, autoimmune disorders, rheumatoid arthritis, and cancer, an increased demand for biologics in disease treatment has been observed in recent years.

Biologics such as recombinant proteins and peptides present multiple benefits, including heightened target specificity, good safety profiles, low toxicity, and reduced likelihood of off-target effects. Notably, many pharmaceutical firms are focusing on the advancement of innovative drug conjugates, including peptide drug conjugates, peptide therapeutics, and cell-penetrating peptides to address a wide array of diseases. Moreover, recent progress in this area has resulted in the authorization and clinical application of peptide medications for disorders such as type 2 diabetes, obesity, and several cancers. We are led to believe that the market is likely to achieve notable growth in the foreseeable future.

Peptide Therapeutics Market: Key Insights

The report delves into the current state of the peptide therapeutics market and identifies potential growth opportunities within industry. Some key findings from the report include:

  • With 25 approved drugs and over 280 candidates under development, peptide therapeutics currently represent one of the fastest growing drug classes, capable of treating a diverse range of diseases.
Peptide Therapeutics Market - IMG1
  • The pipeline features a variety of peptides being evaluated for delivery via different routes, and mostly intended for treating metabolic and oncological disorders
  • In lieu of the growing competition from several viable candidate therapies, innovators are putting in significant efforts to ensure that their proprietary offerings are both clinically and commercially differentiated.
  • Over 1,200 peptide focused clinical trials have been registered across the world; presently, most of these studies are evaluating product candidates intended for the treatment of metabolic diseases.
  • The growing interest in this field is also evident in the increase in recent partnership activity; majority of the deals were focused on technology and / or product licensing.
Peptide Therapeutics Market - IMG2
  • Foreseeing promising returns, many public and private sector investors have invested over USD 7 billion, across more than 200 instances.
Peptide Therapeutics Market - IMG3
  • In order to tap into the lucrative opportunity in this rapidly growing market, several big pharma players have undertaken initiatives, ranging from proprietary product development to strategic investments, in this direction.
  • With a promising development pipeline and encouraging clinical outcomes, the peptide therapeutics market is anticipated to grow at an annualized rate of 6.8%, over the next decade.

Peptide Therapeutics Market: Key Segments

Medium Size Peptides in the Peptide Therapeutics Industry Holds the Largest Share

In the current year, medium sized peptides capture the majority (close to 65% of the market) share. This is probably because medium-sized peptides (ranging from 10 to 40 amino acids) effectively strike a balance between larger proteins and smaller molecules. It is worth highlighting that, small peptides will grow at a CAGR of more than 20% during the forecast period, owing to the increasing usage in manufacturing target specific drugs.

Subcutaneous Route of Administration to Dominate the Peptide Therapeutics Market

The overall market is segmented into intravenous, oral, subcutaneous, topical, and others. In the current year, subcutaneous route of administration accounts for more than 65% of the overall market. The subcutaneous route can avoid the gastrointestinal tract and liver (first-pass metabolism), resulting in greater therapeutic effectiveness. Owing to the ongoing demand for non-invasive or target specific routes of administration, the topical route of administration is likely to grow at a CAGR of ~30% during the forecast period.

Metabolic Diseases Segment to Hold the Highest Peptide Therapeutics Market

Currently, the metabolic diseases segment is likely to capture more than 60% of the overall market share. This is attributed to the increasing need for peptide-based therapies aimed at addressing metabolic conditions like diabetes and obesity. Notably, the peptide therapeutics market for gastrointestinal diseases will expand with a higher CAGR of 25% during the forecast period.

North America to Propel in the Peptide Therapeutics Industry in the Coming Years

This segment highlights the distribution of market across various geographies, such as North America, Europe and Asia-Pacific. According to our projections, North America accounts for the majority of the market share in the current year, and this trend is unlikely to change in the future. According to the report of Centers for Disease Control and Prevention, nearly 129 million people in the United States have at least one or more chronic disease such as diabetes, obesity, heart disease, and hypertension. This is leading to growing demand for peptide therapeutics in this region. It is worth highlighting that the market in Asia-Pacific is likely to grow at a relatively higher CAGR during the forecast period.

Example Players in the Peptide Therapeutics Market

  • Apellis Pharmaceuticals
  • BioLineRx
  • Eli Lilly
  • FirstString Research
  • Novo Nordisk
  • Palatin Technologies
  • RegeneRx Biopharmaceuticals
  • Stealth BioTherapeutics
  • Takeda
  • Zealand Pharma

Peptide Therapeutics Market: Research Coverage

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the peptide therapeutics market, focusing on key market segments, including [A] type of peptide, [B] route of administration, [C] key therapeutic area, [D] geographical regions.
  • Market Landscape: provides a detailed assessment of over 300 peptide-based therapies that are currently approved or are in different stages of development, based on several relevant parameters, such as [A] phase of development, [B] type of peptide, [C] route of administration, [D] key therapeutic areas, [E] year of establishment, [F] company size, and [G] location of headquarters.
  • Company Profiles: In-depth profiles of prominent players engaged in this domain, focusing on [A] year of establishment, [B] location of headquarters, [C] peptide details [D] recent developments and [E] an informed future outlook.
  • Big Pharma Initiatives: An analysis of top big biopharma players engaged in the field of therapeutic peptides, based on several parameters, including [A] number of amino acids, [B] route of administration and [C] therapeutic area.
  • Partnerships and Collaborations An insightful analysis of the partnerships and collaborations inked between stakeholders engaged in the peptide therapeutics market based on various relevant parameters, including [A] year of partnership, [B] type of partnership, [C] type of partner and [D] most active players.
  • Funding and Investment Analysis: A comprehensive examination of various funding and investments raised by developers of peptide therapeutics, based on relevant parameters, including [A] such as year of funding, [B] amount invested [C] type of funding, [D] regional distribution, and [E] most active players.
  • Clinical Trial Analysis: A detailed review of completed, ongoing, and planned clinical studies of various therapeutic peptides, based on relevant parameters, such as [A] trail registration year, [B] phase of development, [C] current trial status and [D] enrolled patient population.
  • Case Study 1: A case study focused on the role of service providers that operate within the peptide therapeutics market and captures information on the various CROs, CMOs and custom peptide manufacturers that are actively involved in this segment of the peptide therapeutics market.
  • Case Study 2: A case study presenting the key characteristics of novel peptides drugs, along with information on the applications, advantages and key challenges involved in their development processes.

Key Questions Answered in this Report

  • How many companies are currently engaged in this market?
  • Which are the leading companies in this market?
  • What is the current global capacity of developers?
  • What factors are likely to influence the evolution of this market?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Additional Benefits

  • Complimentary PPT Insights Packs
  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 15% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Structure of Peptides
  • 3.3. Classification of Peptides
  • 3.4. Modification of Peptides
    • 3.4.1. N-Terminal Modifications
    • 3.4.2. Internal Modifications
    • 3.4.3. C-Terminal Modifications
    • 3.4.4. Other Modifications
  • 3.5. Evolution of Peptide Therapeutics
  • 3.6. Design and Development of Peptide Therapeutics
    • 3.6.1. Traditional versus Novel Peptide Technologies
  • 3.7. Advantages and Disadvantages of Peptide Therapeutics
  • 3.8. Applications of Peptide Therapeutics
  • 3.9. Future Perspectives

4. MARKET OVERVIEW

  • 4.1. Chapter Overview

4.2. Peptide Therapeutics: Overall Market Overview

    • 4.2.1. Analysis by Phase of Development
    • 4.2.2. Analysis by Type of Peptide
    • 4.2.3. Analysis by Route of Administration
    • 4.2.4. Analysis by Phase of Development and Route of Administration
    • 4.2.5. Analysis by Therapeutic Area
    • 4.2.6. Analysis by Phase of Development and Therapeutic Area
    • 4.2.7. Analysis by Route of Administration and Therapeutic Area
    • 4.2.8. Analysis by Phase of Development, Route of Administration and Therapeutic Area (Grid Representation)

5. COMPETITIVE LANDSCAPE

  • 5.1. Chapter Overview
  • 5.2. Peptide Therapeutics: List of Developers
    • 5.2.1. Analysis by Year of Establishment
    • 5.2.2. Analysis by Company Size
    • 5.2.3. Analysis by Geography
    • 5.2.4. Analysis by Phase of Development and Geography (Logo Landscape)
    • 5.2.5.Key Players: Analysis by Number of Product Candidates
  • 5.3.Analysis by Company Size, Key Therapeutic Area and Geography (Heat Map Representation)

6. COMPANY PROFILES

  • 6.1. Chapter Overview
  • 6.2. Apellis Pharmaceuticals
    • 6.2.1. Company Overview
    • 6.2.2 Pipeline Details
    • 6.2.2. Recent Developments and Future Outlook
  • 6.3. BioLineRx
    • 6.3.1. Company Overview
    • 6.3.2. Pipeline Details
    • 6.3.3. Recent Developments and Future Outlook
  • 6.4. Eli Lilly
    • 6.4.1. Company Overview
    • 6.4.2. Financial Information
    • 6.4.3. Pipeline Details
    • 6.4.4. Recent Developments and Future Outlook
  • 6.5. FirstString Research
    • 6.5.1. Company Overview
    • 6.5.2. Pipeline Details
    • 6.5.3. Recent Developments and Future Outlook
  • 6.6. Novo Nordisk
    • 6.6.1. Company Overview
    • 6.6.2. Financial Information
    • 6.6.3. Pipeline Details
    • 6.6.4. Recent Developments and Future Outlook
  • 6.7. Palatin Technologies
    • 6.7.1. Company Overview
    • 6.7.2. Financial Information
    • 6.7.3. Pipeline Details
    • 6.7.4. Recent Developments and Future Outlook
  • 6.8. RegeneRx Biopharmaceuticals
    • 6.8.1. Company Overview
    • 6.8.2. Pipeline Details
    • 6.8.3. Recent Developments and Future Outlook
  • 6.9. Stealth BioTherapeutics
    • 6.9.1. Company Overview
    • 6.9.2. Pipeline Details
    • 6.9.3. Recent Developments and Future Outlook
  • 6.10. Takeda
    • 6.10.1. Company Overview
    • 6.10.2. Financial Information
    • 6.10.3. Pipeline Details
    • 6.10.4. Recent Developments and Future Outlook
  • 6.11. Zealand Pharma
    • 6.11.1. Company Overview
    • 6.11.2. Financial Information
    • 6.11.3. Pipeline Details
    • 6.11.4. Recent Developments and Future Outlook

7. PEPTIDE THERAPEUTICS FOCUSED INITIATIVES OF BIG PHARMA PLAYERS

  • 7.1. Chapter Overview
  • 7.2. Top Pharmaceutical Companies: Peptide Therapeutics Focused Initiatives
    • 7.2.1. Analysis by Number of Amino Acids
    • 7.2.2. Analysis by Route of Administration
    • 7.2.3. Analysis by Therapeutic Area
  • 7.3. Benchmark Analysis of Key Parameters
    • 7.3.1. Spider Web Analysis: Pipeline Strength
    • 7.3.2. Spider Web Analysis: Partnerships and Collaborations
    • 7.3.3. Spider Web Analysis: Funding and Investments
    • 7.3.4. Spider Web Analysis: Clinical Trials
  • 7.4. Benchmark Analysis of Big Pharmaceutical Players
    • 7.4.1. Spider Web Analysis: Novo Nordisk
    • 7.4.2. Spider Web Analysis: Amgen
    • 7.4.3. Spider Web Analysis: Takeda
    • 7.4.4. Spider Web Analysis: Eli Lilly
    • 7.4.5. Spider Web Analysis: Johnson and Johnson

8. PARTNERSHIPS AND COLLABORATIONS

  • 8.1. Chapter Overview
  • 8.2. Partnership Models
  • 8.3. Peptide Therapeutics: List of Partnerships and Collaborations
    • 8.3.1. Analysis by Year of Partnership
    • 8.3.2. Analysis by Type of Partnership
    • 8.3.3. Analysis by Year and Type of Partnership
    • 8.3.4. Analysis by Focus Area
    • 8.3.5. Analysis by Type of Partnership and Focus Area
    • 8.3.6. Analysis by Type of Peptide
    • 8.3.7. Analysis by Route of Administration
    • 8.3.8. Analysis by Route of Administration and Geography
    • 8.3.9. Analysis by Type of Partnership and Phase of Development
    • 8.3.10. Analysis by Therapeutic Area
    • 8.3.11. Analysis by Type of Partnership and Therapeutic Area
  • 8.4. Most Active Players: Analysis by Number of Partnerships
  • 8.5. Regional Analysis
    • 8.5.1. Intracontinental and Intercontinental Agreements
    • 8.5.2. Local and International Agreements

9. FUNDING AND INVESTMENT ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Types of Funding
  • 9.3. Peptide Therapeutics: Funding and Investment Analysis
    • 9.3.1. Analysis by Number of Funding Instances
    • 9.3.2. Analysis by Amount Invested
    • 9.3.3. Analysis by Type of Funding
    • 9.3.4. Analysis by Year and Type of Funding
    • 9.3.5. Analysis of Amount Invested by Geography
    • 9.3.6. Most Active Players: Analysis by Number of Funding Instances and Amount Invested
    • 9.3.7. Key Investors: Analysis by Number of Funding Instances
    • 9.3.8. Analysis by Phase of Development
    • 9.3.9. Analysis by Therapeutic Area

10. CLINICAL TRIAL ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Scope and Methodology
  • 10.3. Peptide Therapeutics: Clinical Trial Analysis
    • 10.3.1. Analysis by Trial Registration Year
    • 10.3.2. Analysis by Trial Status
    • 10.3.3. Analysis by Trial Phase
    • 10.3.4. Analysis by Trial Recruitment Status
    • 10.3.5. Analysis by Trial Registration Year and Enrolled Patient Population
    • 10.3.6. Analysis by Study Design
    • 10.3.7. Analysis by Type of Sponsor / Collaborator
    • 10.3.8. Most Active Players: Analysis by Number of Registered Trials
    • 10.3.9. Emerging Focus Area
    • 10.3.10. Analysis by Therapeutic Area
    • 10.3.11. Geographical Analysis by Number of Registered Trials
    • 10.3.12. Geographical Analysis by Enrolled Patient Population

11. CLINICAL AND COMMERCIAL ATTRACTIVENESS ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Methodology
    • 11.2.1. Assumptions and Key Parameters
  • 11.3. Affiliated Insights
    • 11.3.1. Clinical and Commercial Attractiveness Analysis: Autoimmune Diseases
    • 11.3.2. Clinical and Commercial Attractiveness Analysis: Central Nervous System (CNS) Diseases
    • 11.3.3. Clinical and Commercial Attractiveness Analysis: Endocrine Diseases
    • 11.3.4. Clinical and Commercial Attractiveness Analysis: Gastrointestinal Diseases
    • 11.3.5. Clinical and Commercial Attractiveness Analysis: Genetic Diseases
    • 11.3.6. Clinical and Commercial Attractiveness Analysis: Hematological Diseases
    • 11.3.7. Clinical and Commercial Attractiveness Analysis: Infectious Diseases
    • 11.3.8. Clinical and Commercial Attractiveness Analysis: Inflammatory Diseases
    • 11.3.9. Clinical and Commercial Attractiveness Analysis: Metabolic Diseases
    • 11.3.10. Clinical and Commercial Attractiveness Analysis: Oncological Diseases
    • 11.3.11. Clinical and Commercial Attractiveness Analysis: Ophthalmic Diseases
    • 11.3.12. Clinical and Commercial Attractiveness Analysis: Other Diseases

12. CASE STUDY: CONTRACT SERVICES LANDSCAPE

  • 12.1. Chapter Overview
    • 12.1.1. Chapter Overview
  • 12.2. Role of Service Providers
    • 12.2.1. List of Peptide CROs
    • 12.2.2. List of Platform Providers
    • 12.2.3. List of Peptide CMOs
      • 12.2.3.1. List of Custom Peptide Manufacturers
  • 12.3. Advantages of Outsourcing
  • 12.4. Risks and Challenges Associated with Outsourcing

13. CASE STUDY: NOVEL PEPTIDE THERAPEUTICS

  • 13.1. Chapter Overview
  • 13.2. Overview of Novel Peptide Therapeutics
  • 13.3. Advantages and Applications of Novel Peptide Therapeutics
  • 13.4. Key Challenges Associated with Novel Peptide Therapeutics

14. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 14.1. Chapter Overview
  • 14.2. Scope and Limitations
  • 14.3. Key Assumptions and Forecast Methodology
  • 14.4. Global Peptide Therapeutics Market, till 2030
    • 14.4.1. Global Peptide Therapeutics Market, till 2030: Distribution by Type of Peptide
    • 14.4.2. Peptide Therapeutics Market, till 2030: Distribution by Number of Amino Acids
    • 14.4.3. Peptide Therapeutics Market, till 2030: Distribution by Route of Administration
    • 14.4.4. Peptide Therapeutics Market, till 2030: Distribution by Geography
    • 14.4.5. Peptide Therapeutics Market, till 2030: Distribution by Key Therapeutic Area
  • 14.5. Autoimmune Diseases
    • 14.5.1. Value Creation Analysis
    • 14.5.2. Sales Forecast for Approved Peptide Therapeutics
      • 14.5.2.1. Tymlos (R)
    • 14.5.3. Sales Forecast for Clinical Peptide Therapeutics
      • 14.5.3.1. Ampion / DMI 9523
      • 14.5.3.2. TBRIA
  • 14.6. Cardiovascular Diseases
    • 14.6.1. Value Creation Analysis
    • 14.6.2. Sales Forecast for Approved Peptide Therapeutics
      • 14.6.2.1. Giapreza (R)
  • 14.7. CNS Diseases
    • 14.7.1. Value Creation Analysis
    • 14.7.2. Sales Forecast for Clinical Peptide Therapeutics
      • 14.7.2.1. Nerinitide
      • 14.7.2.2. Rybelsus (R)
  • 14.8. Dermatological Diseases
    • 14.8.1. Value Creation Analysis
    • 14.8.2. Sales Forecast for Approved Peptide Therapeutics
      • 14.8.2.1. Melgain
  • 14.9. Endocrine Diseases
    • 14.9.1. Value Creation Analysis
    • 14.9.2. Sales Forecast for Approved Peptide Therapeutics
      • 14.9.2.1. Parsabiv (R)
      • 14.9.2.2. Lupykins
    • 14.9.3. Sales Forecast for Clinical Peptide Therapeutics
      • 14.9.3.1. Difelikefalin / KORSUVA / Oral CR845
  • 14.10. Gastrointestinal Diseases
    • 14.10.1. Value Creation Analysis
    • 14.10.2. Sales Forecast for Approved Peptide Therapeutics
      • 14.10.2.1. Gattex (R)
      • 14.10.2.2. Trulance (R)
    • 14.10.3. Sales Forecast for Clinical Peptide Therapeutics
      • 14.10.3.1. Glepaglutide / ZP1848
      • 14.10.3.2. Larazotide / INN-202
  • 14.11. Genetic Diseases
    • 14.11.1. Value Creation Analysis
    • 14.11.2. Sales Forecast for Approved Peptide Therapeutics
      • 14.11.2.1. Scenesse (R)
    • 14.11.3. Sales Forecast for Clinical Peptide Therapeutics
      • 14.11.3.1. Elamipretide / MTP-131
      • 14.11.3.2. Ninlaro (R)
      • 14.11.3.3. Vosoritide / BMN 111
      • 14.11.3.4. Zilucoplan / RA101495
  • 14.12. Hematological Diseases
    • 14.12.1. Value Creation Analysis
    • 14.12.2. Sales Forecast for Clinical Peptide Therapeutics
      • 14.12.2.1. Pegcetacoplan / APL-2
  • 14.13. Infectious Diseases
    • 14.13.1. Value Creation Analysis
    • 14.13.2. Sales Forecast for Approved Peptide Therapeutics
      • 14.13.2.1. Solnatide
    • 14.13.3. Sales Forecast for Clinical Peptide Therapeutics
      • 14.13.3.1. Aikening / Albuvirtide
      • 14.13.3.2. Reltecimod
  • 14.14. Inflammatory Diseases
    • 14.14.1. Value Creation Analysis
    • 14.14.2. Sales Forecast for Clinical Peptide Therapeutics
      • 14.14.2.1. Lupuzor
  • 14.15. Metabolic Diseases
    • 14.15.1. Value Creation Analysis
    • 14.15.2. Sales Forecast for Approved Peptide Therapeutics
      • 14.15.2.1. Adlyxin (R)
      • 14.15.2.6. Imcivree (TM)
      • 14.15.2.3. Mycapssa (R)
      • 14.15.2.5. Ozempic (R)
      • 14.15.2.4. Rybelsus (R)
      • 14.15.2.7. Tanzeum (R)
      • 14.15.2.8. Tresiba (R)
      • 14.15.2.2. Trulicity (R)
      • 14.15.2.10. Zegalogue (R)
    • 14.15.3. Sales Forecast for Clinical Peptide Therapeutics
      • 14.15.3.1. Imcivree (TM)
      • 14.15.3.2. Ozempic
      • 14.15.3.3. Tirzepatide / LY3298176
  • 14.16. Oncological Diseases
    • 14.16.1. Value Creation Analysis
    • 14.16.2. Sales Forecast for Approved Peptide Therapeutics
      • 14.16.2.1. Aplidin (R)
      • 14.16.2.2. Lupron (R)
      • 14.16.2.3. Lutathera (R)
      • 14.16.2.4. Ninlaro (R)
    • 14.16.3. Sales Forecast for Clinical Peptide Therapeutics
      • 14.16.3.1. Balixafortide / POL6326
      • 14.16.3.2. Dusquetide / SGX942
      • 14.16.3.3. Motixafortide / BL-8040
  • 14.17. Ophthalmic Diseases
    • 14.17.1. Value Creation Analysis
    • 14.17.2. Sales Forecast for Clinical Peptide Therapeutics
      • 14.17.2.1. RGN-259 / GBT-201
      • 14.17.2.2. Pegcetacoplan / APL-2
      • 14.17.2.3. XG-102
  • 14.19. Other Diseases
    • 14.19.1. Value Creation Analysis
    • 14.19.2. Sales Forecast for Approved Peptide Therapeutics
      • 14.19.2.1. Lupron (R)
      • 14.19.2.2. Vyleesi (TM)
      • 14.19.2.3. Xylentra (TM)
    • 14.19.3. Sales Forecast for Clinical Peptide Therapeutics
      • 14.19.3.1. BP-101
      • 14.19.3.2. Granexin
      • 14.19.3.3. Ensereptide / PXL01

15. CONCLUDING REMARKS

  • 15.1. Chapter Overview

16. APPENDIX I: LIST OF APPROVED PEPTIDE THERAPEUTICS

17. APPENDIX II: TABULATED DATA

18. APPENDIX III: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

  • Table 4.1 Peptide Therapeutics: Development Pipeline
  • Table 5.1 Peptide Therapeutics: List of Drug Developers
  • Table 6.1 Apellis Pharmaceuticals: Key Highlights
  • Table 6.2 Apellis Pharmaceuticals: Peptide-based Drugs Portfolio
  • Table 6.3 Apellis Pharmaceuticals: Recent Developments and Future Outlook
  • Table 6.4 BioLineRx: Key Highlights
  • Table 6.5 BioLineRx: Peptide-based Drugs Portfolio
  • Table 6.6 Eli Lilly: Key Highlights
  • Table 6.7 Eli Lilly: Peptide-based Drugs Portfolio
  • Table 6.8 FirstString Research: Key Highlights
  • Table 6.9 FirstString Research: Peptide-based Drugs Portfolio
  • Table 6.10 Novo Nordisk: Key Highlights
  • Table 6.11 Novo Nordisk: Peptide-based Drugs Portfolio
  • Table 6.12 Novo Nordisk: Recent Developments and Future Outlook
  • Table 6.13 Palatin Technologies: Key Highlights
  • Table 6.14 Palatin Technologies: Peptide-based Drugs Portfolio
  • Table 6.15 RegeneRx Biopharmaceuticals: Key Highlights
  • Table 6.16 RegeneRx Biopharmaceuticals: Peptide-based Drugs Portfolio
  • Table 6.17 RegeneRx Biopharmaceuticals: Recent Developments and Future Outlook
  • Table 6.18 Stealth BioTherapeutics: Key Highlights
  • Table 6.19 Stealth BioTherapeutics: Peptide-based Drugs Portfolio
  • Table 6.20 Stealth BioTherapeutics: Recent Developments and Future Outlook
  • Table 6.21 Takeda: Key Highlights
  • Table 6.22 Takeda: Peptide-based Drugs Portfolio
  • Table 6.23 Zealand Pharma: Key Highlights
  • Table 6.24 Zealand Pharma: Peptide-based Drugs Portfolio
  • Table 6.25 Zealand Pharma: Recent Developments and Future Outlook
  • Table 7.1 Partnerships and Collaborations: List of Peptide Therapeutics Initiatives Undertaken by Big Pharma Players
  • Table 8.1 Peptide Therapeutics: List of Partnerships and Collaborations, since 2015
  • Table 9.1 Peptide Therapeutics: List of Funding and Investments, since 2015
  • Table 9.2 Funding and Investment Analysis: Summary of Investments
  • Table 9.3 Funding and Investment Analysis: Summary of Venture Capital Funding
  • Table 12.1 Peptides and Macrocycle Drug Discovery: List of Service Providers
  • Table 12.2 Peptides and Macrocycle Drug Discovery Platform Providers: Information on Types of Peptide Discovered
  • Table 12.3 Peptide Therapeutics: List of Contract Peptide API Manufacturers
  • Table 12.4 Peptide Therapeutics: List of Custom Peptide Manufacturers
  • Table 13.1 Peptide Therapeutics: List of Novel Peptide Therapeutics
  • Table 14.1 Value Creation Analysis: Information on Approved and Clinical Stage Peptide Therapeutics for Autoimmune Diseases
  • Table 14.2 Value Creation Analysis: Information on Approved and Clinical Stage Peptide Therapeutics for Cardiovascular Diseases
  • Table 14.3 Value Creation Analysis: Information on Clinical Stage Peptide Therapeutics for CNS Diseases
  • Table 14.4 Value Creation Analysis: Information on Approved Peptide Therapeutics for Dermatological Diseases
  • Table 14.5 Value Creation Analysis: Information on Approved and Clinical Stage Peptide Therapeutics for Endocrine Diseases
  • Table 14.6 Value Creation Analysis: Information on Approved and Clinical Stage Peptide Therapeutics for Gastrointestinal Diseases
  • Table 14.7 Value Creation Analysis: Information on Approved and Clinical Stage Peptide Therapeutics for Genetic Diseases
  • Table 14.8 Value Creation Analysis: Information on Clinical Stage Peptide Therapeutics for Hematological Diseases
  • Table 14.9 Value Creation Analysis: Information on Clinical Stage Peptide Therapeutics for Infectious Diseases
  • Table 14.10 Value Creation Analysis: Information on Clinical Stage Peptide Therapeutics for Inflammatory Diseases
  • Table 14.11 Value Creation Analysis: Information on Approved and Clinical Stage Peptide Therapeutics for Metabolic Diseases
  • Table 14.12 Value Creation Analysis: Information on Approved and Clinical Stage Peptide Therapeutics for Oncological Diseases
  • Table 14.13 Value Creation Analysis: Information on Clinical Stage Peptide Therapeutics for Ophthalmic Diseases
  • Table 14.14 Value Creation Analysis: Information on Approved and Clinical Stage Peptide for Other Diseases
  • Table 17.1 Peptide Therapeutics: Distribution by Phase of Development
  • Table 17.2 Peptide Therapeutics: Distribution by Type of Peptide
  • Table 17.3 Peptide Therapeutics: Distribution by Route of Administration
  • Table 17.4 Peptide Therapeutics: Distribution by Phase of Development and Route of Administration
  • Table 17.5 Peptide Therapeutics: Distribution by Therapeutic Area
  • Table 17.6 Peptide Therapeutics: Distribution by Phase of Development and Therapeutic Area
  • Table 17.7 Peptide Therapeutics: Distribution by Route of Administration and Key Therapeutic Area
  • Table 17.8 Peptide Therapeutics Developers: Distribution by Year of Establishment
  • Table 17.9 Peptide Therapeutics Developers: Distribution by Company Size
  • Table 17.10 Peptide Therapeutics Developers: Distribution by Geography
  • Table 17.11 Peptide Therapeutics Developers: Key Players
  • Table 17.12 Peptide Therapeutics Developers: Distribution by Key Players and Phase of
  • Table 17.13 Eli Lilly: Annual Revenues, FY 2015 Onwards (USD Million)
  • Table 17.14 Novo Nordisk: Annual Revenues, FY 2015 Onwards (DKK Million)
  • Table 17.15 Palatin Technologies: Annual Revenues, FY 2015 Onwards (USD Million)
  • Table 17.16 Takeda: Annual Revenues, FY 2015 Onwards (JPY Million)
  • Table 17.17 Zealand Pharma: Annual Revenues, FY 2015 Onwards (DKK Million)
  • Table 17.18 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Table 17.19 Partnerships and Collaborations: Distribution by Year of Partnership
  • Table 17.20 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 17.21 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Table 17.22 Partnerships and Collaborations: Distribution by Focus Area
  • Table 17.23 Partnerships and Collaborations: Distribution by Type of Partnership and Focus Area
  • Table 17.24 Partnerships and Collaborations: Distribution by Type of Peptide
  • Table 17.25 Partnerships and Collaborations: Distribution by Route of Administration
  • Table 17.26 Partnerships and Collaborations: Distribution by Route of Administration and Geography
  • Table 17.27 Partnerships and Collaborations: Distribution by Type of Partnership and Phase of Development
  • Table 17.28 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Table 17.29 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
  • Table 17.30 Most Active Players: Distribution by Number of Partnerships
  • Table 17.31 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
  • Table 17.32 Partnerships and Collaborations: Local and International Agreements
  • Table 17.33 Funding and Investment Analysis: Cumulative Year-wise Distribution by Number of Instances
  • Table 17.34 Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested, since 2015 (USD Million)
  • Table 17.35 Funding and Investment Analysis: Distribution of Instances by Type of Funding, since 2015
  • Table 17.36 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding, since 2015 (USD Million)
  • Table 17.37 Funding and Investment Analysis: Distribution by Year and Type of Funding, since 2015
  • Table 17.38 Funding and Investment Analysis: Summary of Investments, since 2015 (USD Million)
  • Table 17.39 Funding and Investment Analysis: Distribution by Geography
  • Table 17.40 Funding and Investment Analysis: Regional Distribution of Funding Instances
  • Table 17.41 Most Active Players: Distribution by Number of Funding Instances
  • Table 17.42 Most Active Players: Distribution by Amount Invested (USD Million)
  • Table 17.43 Funding and Investment Analysis: Distribution by Type of Investors
  • Table 17.44 Funding and Investment Analysis: Distribution by Leading Investors
  • Table 17.45 Funding and Investment Analysis: Distribution of Instances by Phase of Development
  • Table 17.46 Funding and Investment Analysis: Distribution by Therapeutic Area
  • Table 17.47 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year
  • Table 17.48 Clinical Trial Analysis: Distribution by Trial Status
  • Table 17.49 Clinical Trial Analysis: Distribution by Trial Phase
  • Table 17.50 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Recruitment Status
  • Table 17.51 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year,
  • Table 17.52 Clinical Trial Analysis: Distribution by Study Design
  • Table 17.53 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Table 17.54 Most Active Players: Distribution by Number of Registered Trials
  • Table 17.55 Clinical Trial Analysis: Distribution by Therapeutic Area
  • Table 17.56 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
  • Table 17.57 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
  • Table 17.58 Global Peptide Therapeutics Market, till 2030 (USD Billion)
  • Table 17.59 Peptide Therapeutics Market: Distribution by Type of Peptide, till 2030
  • Table 17.60 Peptide Therapeutics Market: Distribution by Route of Administration, till 2030
  • Table 17.61 Peptide Therapeutics Market: Distribution by Geography, till 2030
  • Table 17.62 Peptide Therapeutics Market: Distribution by Therapeutic Area, till 2030
  • Table 17.63 Peptide Therapeutics Market for Autoimmune Diseases, till 2030 (USD Billion)
  • Table 17.64 Peptide Therapeutics Market for Cardiovascular Diseases, till 2030 (USD Billion)
  • Table 17.65 Peptide Therapeutics Market for CNS Diseases, till 2030 (USD Billion)
  • Table 17.66 Peptide Therapeutics Market for Dermatological Diseases, till 2030 (USD Billion)
  • Table 17.67 Peptide Therapeutics Market for Endocrine Diseases, till 2030 (USD Billion)
  • Table 17.68 Peptide Therapeutics Market for Gastrointestinal Diseases, till 2030 (USD Billion)
  • Table 17.69 Peptide Therapeutics Market for Genetic Diseases, till 2030 (USD Billion)
  • Table 17.70 Peptide Therapeutics Market for Hematological Diseases, till 2030 (USD Billion)
  • Table 17.71 Peptide Therapeutics Market for Infectious Diseases, till 2030 (USD Billion)
  • Table 17.72 Peptide Therapeutics Market for Inflammatory Diseases, till 2030 (USD Billion)
  • Table 17.73 Peptide Therapeutics Market for Metabolic Diseases, till 2030 (USD Billion)
  • Table 17.74 Peptide Therapeutics Market for Oncological Diseases, till 2030 (USD Billion)
  • Table 17.75 Peptide Therapeutics Market for Ophthalmic Diseases, till 2030 (USD Billion)
  • Table 17.76 Peptide Therapeutics Market for Other Diseases, till 2030 (USD Billion)

List of Figures

  • Figure 3.1 Peptide Modification Techniques
  • Figure 3.2 Historical Timeline of Peptide Therapeutics
  • Figure 4.1 Peptide Therapeutics: Distribution by Phase of Development
  • Figure 4.2 Peptide Therapeutics: Distribution by Type of Peptide
  • Figure 4.3 Peptide Therapeutics: Distribution by Route of Administration
  • Figure 4.4 Peptide Therapeutics: Distribution by Phase of Development and Route of Administration
  • Figure 4.5 Peptide Therapeutics: Distribution by Therapeutic Area
  • Figure 4.6 Peptide Therapeutics: Distribution by Phase of Development and Therapeutic Area
  • Figure 4.7 Peptide Therapeutics: Distribution by Route of Administration and Key Therapeutic Area
  • Figure 4.8 Grid Representation: Distribution by Phase of Development, Route of Administration and Key Therapeutic Area
  • Figure 5.1 Peptide Therapeutics Developers: Distribution by Year of Establishment
  • Figure 5.2 Peptide Therapeutics Developers: Distribution by Company Size
  • Figure 5.3 Peptide Therapeutics Developers: Distribution by Geography
  • Figure 5.4 Regional Landscape: Distribution of Peptide Therapeutics Developers by Phase of Development and Geography
  • Figure 5.5 Peptide Therapeutics Developers: Key Players
  • Figure 5.6 Peptide Therapeutics Developers: Distribution by Key Players and Phase of Development
  • Figure 5.7 Heat Map Representation: Distribution by Company Size, Key Therapeutic Area and Geography
  • Figure 6.1 Eli Lilly: Annual Revenues, FY 2015 Onwards (USD Million)
  • Figure 6.2 Novo Nordisk: Annual Revenues, FY 2015 Onwards (DKK Million)
  • Figure 6.3 Palatin Technologies: Annual Revenues, FY 2015 Onwards (USD Million)
  • Figure 6.4 Takeda: Annual Revenues, FY 2015 Onwards (JPY Million)
  • Figure 6.5 Zealand Pharma: Annual Revenues, FY 2015 Onwards (DKK Million)
  • Figure 7.1 Harvey Ball Analysis: Big Pharma Investment Summary
  • Figure 7.2 Big Pharma Players: Distribution by Number of Amino Acids
  • Figure 7.3 Big Pharma Players: Distribution by Route of Administration
  • Figure 7.4 Big Pharma Players: Distribution by Therapeutic Area
  • Figure 7.5 Spider Web Analysis: Pipeline Strength
  • Figure 7.6 Spider Web Analysis: Partnerships and Collaborations
  • Figure 7.7 Partnerships and Collaborations: Distribution by Year and Type of Partnership Undertaken by Big Pharma Players
  • Figure 7.8 Spider Web Analysis: Funding and Investments
  • Figure 7.9 Spider Web Analysis: Clinical Trials
  • Figure 7.10 Spider Web Analysis: Novo Nordisk
  • Figure 7.11 Spider Web Analysis: Amgen
  • Figure 7.12 Spider Web Analysis: Takeda
  • Figure 7.13 Spider Web Analysis: Eli Lilly
  • Figure 7.14 Spider Web Analysis: Johnson and Johnson
  • Figure 8.1 Partnerships and Collaborations: Distribution by Year of Partnership
  • Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 8.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Figure 8.4 Partnerships and Collaborations: Distribution by Focus Area
  • Figure 8.5 Partnerships and Collaborations: Distribution by Type of Partnership and Focus Area
  • Figure 8.6 Partnerships and Collaborations: Distribution by Type of Peptide
  • Figure 8.7 Partnerships and Collaborations: Distribution by Route of Administration
  • Figure 8.8 Partnerships and Collaborations: Distribution by Route of Administration and Geography
  • Figure 8.9 Partnerships and Collaborations: Distribution by Type of Partnership and Phase of Development
  • Figure 8.10 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Figure 8.11 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
  • Figure 8.12 Most Active Players: Distribution by Number of Partnerships
  • Figure 8.13 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
  • Figure 8.14 Partnerships and Collaborations: Local and International Agreements
  • Figure 9.1 Funding and Investment Analysis: Cumulative Year-wise Distribution by Number of Instances, since 2015
  • Figure 9.2 Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested, since 2015 (USD Million)
  • Figure 9.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding, since 2015
  • Figure 9.4 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding, since 2015 (USD Million)
  • Figure 9.5 Funding and Investment Analysis: Distribution by Year and Type of Funding, since 2015
  • Figure 9.6 Funding and Investment Analysis: Distribution by Year, Type of Funding and Amount Invested, since 2015 (USD Million)
  • Figure 9.7 Funding and Investment Analysis: Summary of Investments, since 2015 (USD Million)
  • Figure 9.8 Funding and Investment Analysis: Distribution by Geography
  • Figure 9.9 Funding and Investment Analysis: Regional Distribution of Funding Instances
  • Figure 9.10 Most Active Players: Distribution by Number of Funding Instances
  • Figure 9.11 Most Active Players: Distribution by Amount Invested (USD Million)
  • Figure 9.12 Funding and Investment Analysis:* Distribution by Type of Investors
  • Figure 9.13 Funding and Investment Analysis: Distribution by Leading Investors
  • Figure 9.13 Funding and Investment Analysis: Distribution of Instances by Phase of Development
  • Figure 9.14 Funding and Investment Analysis: Distribution by Therapeutic Area
  • Figure 10.1 Clinical Trial Analysis: Scope and Methodology
  • Figure 10.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year
  • Figure 10.3 Clinical Trial Analysis: Distribution by Trial Status
  • Figure 10.4 Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 10.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Recruitment Status
  • Figure 10.6 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
  • Figure 10.7 Clinical Trial Analysis: Distribution by Study Design
  • Figure 10.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Figure 10.9 Most Active Players: Distribution by Number of Registered Trials
  • Figure 10.10 Clinical Trial Analysis: Emerging Focus Area
  • Figure 10.11 Clinical Trial Analysis: Distribution by Therapeutic Area
  • Figure 10.12 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
  • Figure 10.13 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
  • Figure 11.1 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: Autoimmune Diseases
  • Figure 11.2 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: CNS Diseases
  • Figure 11.3 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: Endocrine Diseases
  • Figure 11.4 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: Gastrointestinal Diseases
  • Figure 11.5 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: Genetic Diseases
  • Figure 11.6 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: Hematological Diseases
  • Figure 11.7 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: Infectious Diseases
  • Figure 11.8 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: Inflammatory Diseases
  • Figure 11.9 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: Metabolic Diseases
  • Figure 11.10 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: Oncological Diseases
  • Figure 11.11 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: Ophthalmic Diseases
  • Figure 11.12 Clinical and Commercial Attractiveness Analysis: Phase III Molecules: Other Diseases
  • Figure 14.1 Global Peptide Therapeutics Market, till 2030 (USD Billion)
  • Figure 14.2 Peptide Therapeutics Market: Distribution by Type of Peptide, till 2030
  • Figure 14.3 Peptide Therapeutics Market: Distribution by Route of Administration, till 2030
  • Figure 14.4 Peptide Therapeutics Market: Distribution by Geography, till 2030
  • Figure 14.5 Peptide Therapeutics Market: Distribution by Key Therapeutic Area, till 2030
  • Figure 14.6 Peptide Therapeutics Market for Autoimmune Diseases, till 2030 (USD Billion)
  • Figure 14.7 Peptide Therapeutics Market for Cardiovascular Diseases, till 2030 (USD Billion)
  • Figure 14.8 Peptide Therapeutics Market for CNS Diseases, till 2030 (USD Billion)
  • Figure 14.9 Peptide Therapeutics Market for Dermatological Diseases, till 2030 (USD Billion)
  • Figure 14.10 Peptide Therapeutics Market for Endocrine Diseases, till 2030 (USD Billion)
  • Figure 14.11 Peptide Therapeutics Market for Gastrointestinal Diseases, till 2030 (USD Billion)
  • Figure 14.12 Peptide Therapeutics Market for Genetic Diseases, till 2030 (USD Billion)
  • Figure 14.13 Peptide Therapeutics Market for Hematological Diseases, till 2030 (USD Billion)
  • Figure 14.14 Peptide Therapeutics Market for Infectious Diseases, till 2030 (USD Billion)
  • Figure 14.15 Peptide Therapeutics Market for Inflammatory Diseases, till 2030 (USD Billion)
  • Figure 14.16 Peptide Therapeutics Market for Metabolic Diseases, till 2030 (USD Billion)
  • Figure 14.17 Peptide Therapeutics Market for Oncological Diseases, till 2030 (USD Billion)
  • Figure 14.18 Peptide Therapeutics Market for Ophthalmic Diseases, till 2030 (USD Billion)
  • Figure 14.19 Peptide Therapeutics Market for Other Diseases, till 2030 (USD Billion)